erlotinib hydrochloride has been researched along with rifampin in 3 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (rifampin) | Trials (rifampin) | Recent Studies (post-2010) (rifampin) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 20,468 | 1,499 | 6,552 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | rifampin (IC50) |
|---|---|---|---|
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 2.949 | |
| Caspase-1 | Homo sapiens (human) | 8.319 | |
| Alpha-synuclein | Homo sapiens (human) | 7.1 | |
| Enoyl-[acyl-carrier-protein] reductase [NADH] | Mycobacterium tuberculosis H37Rv | 0.03 | |
| DNA-directed RNA polymerase subunit beta | Mycobacterium tuberculosis H37Rv | 0.01 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 1.5 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 1.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beumer, JH; Christner, SM; Gramignoli, R; Parise, RA; Pillai, VC; Rudek, MA; Strom, SC; Venkataramanan, R | 1 |
| Drolet, DW; Fettner, SH; Hamilton, M; Lum, BL; Rakhit, AK; Witt, K; Wolf, JL | 1 |
| Bauer, M; Blaickner, M; Hacker, M; Hernández Lozano, I; Karch, R; Langer, O; Matsuda, A; Wulkersdorfer, B; Zeitlinger, M | 1 |
1 trial(s) available for erlotinib hydrochloride and rifampin
| Article | Year |
|---|---|
The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects.
Topics: Adult; Cytochrome P-450 CYP3A; Drug Interactions; Enzyme Induction; Erlotinib Hydrochloride; Female; Healthy Volunteers; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Rifampin; Young Adult | 2014 |
2 other study(ies) available for erlotinib hydrochloride and rifampin
| Article | Year |
|---|---|
Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer.
Topics: 14-alpha Demethylase Inhibitors; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Erlotinib Hydrochloride; Female; Half-Life; Hepatocytes; HIV Infections; HIV Protease Inhibitors; Humans; Ketoconazole; Male; Middle Aged; Neoplasms; Nucleic Acid Synthesis Inhibitors; Quinazolines; Rifampin; Ritonavir | 2013 |
Towards Improved Pharmacokinetic Models for the Analysis of Transporter-Mediated Hepatic Disposition of Drug Molecules with Positron Emission Tomography.
Topics: Biliary Tract; Biological Transport; Carbon Radioisotopes; Drug Interactions; Erlotinib Hydrochloride; Healthy Volunteers; Humans; Liver; Membrane Transport Proteins; Metabolic Clearance Rate; Models, Biological; Positron-Emission Tomography; Rifampin; Tissue Distribution | 2019 |